Your session is about to expire
← Back to Search
Study Summary
This trial will study a new drug to see if it is safe and works against advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is in an advanced stage and not just in one place.I still have side effects from previous treatments, except for hair loss.I haven't had cancer, except for certain skin cancers or low-risk cancers, in the last 3 years.I do not have any serious, uncontrolled illnesses or infections.I am not pregnant or breastfeeding.I haven't had cancer treatment with drugs or trials within the last 14 days (small molecule) or 28 days (biologic).I have a history of serious heart problems.I have a history of myelodysplastic syndrome or acute myeloid leukemia.I am fully active or can carry out light work.I have had issues with my phosphate or calcium levels.My organs are working well.My brain cancer is getting worse or causing symptoms.I have or am at risk for eye damage affecting my retina.
- Group 1: Expansion as Monotherapy - Part 2
- Group 2: Dose Finding as Monotherapy - Part 1
- Group 3: Dose Finding in Combination - Part 3
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Under what circumstances is UCT-01-097 typically prescribed?
"UCT-01-097 has been clinically proven to be effective in treating metastatic neoplasms, locally advanced non-small cell lung cancer and metastatic bladder cancers."
How risky is exposure to UCT-01-097 for individuals?
"UCT-01-097's safety and efficacy has not been thoroughly vetted yet, thus it received a rating of 1."
What aims does this medical research endeavor seek to accomplish?
"Over the course of two years, this trial seeks to investigate and set a Maximum Tolerated Dose (MTD) for UCT-01-097. Secondary research goals include determining the Terminal Half-Life (t1/2), Apparent Volume of Distribution (Vz/F), and Accumulation Ratio (Rac) via pharmacokinetic assessment."
How many participants has this research project enrolled?
"To carry out this medical research, 1200 Pharma LLC needs to recruit a total of 106 patients who meet the qualifications. The trial will take place in Dallas, Texas at Mary Crowley Cancer Research and UCLA - JCCC Clinical Research Unit in Los Angeles, California."
Is the trial still open to enrolling participants?
"Affirmative. According to the information on clinicaltrials.gov, this research project is actively seeking participants. It was originally posted on March 3rd 2021 and updated most recently on September 8th 2022; 106 people are required from three sites in total for this trial."
Share this study with friends
Copy Link
Messenger